To view or add a comment, sign in Eli Lilly and Company unveiled findings from two late-stage trials at the European Congress on Obesity (#ECO) showing that its newly-approved oral #GLP1 agonist Foundayo (orforglipron) and a lower dose of its dual GIP/GLP-1 agonist Zepbound (tirzepatide), each helped sustain #weightloss in individuals who had previously dropped their weight on higher doses of injectable incretin therapies
Future investigations might focus on characterizing the specific signaling cascades influenced by this combination and identifying novel implications in emerging fields like synthetic biology and bioinformatics
Similarly, in a cross-sectional study by Johnson et al., analysis of 3-day food records in individuals using GLP-1 RA for at least one month showed that 75% of participants reported having increased their protein intake after treatment, yet only 43% achieved the recommended intake of 1.2 g/kg/day
We initially opted out of marketing texts after signing up, and an automated email then told us our messages were blocked and we would not be approved for a prescription until we resumed texts from the clinic
But according to conservative estimates, 2 million patients have taken compounded GLP-1s, which are not approved by the U.S
Another misconception is that IV glutathione is the only "real" way to get results